Neurocrine Biosciences NBIX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's short-term investments?
- Neurocrine Biosciences (NBIX) reported short-term investments of $1.05B in Q1 2026.
- How has Neurocrine Biosciences's short-term investments changed year-over-year?
- Neurocrine Biosciences's short-term investments increased by 40.1% year-over-year, from $749.4M to $1.05B.
- What is the long-term trend for Neurocrine Biosciences's short-term investments?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's short-term investments has grown at a 4.6% compound annual growth rate (CAGR), from $613.9M to $767.4M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.